Residual Inflammatory Risk in Contemporary Coronary Intervention: Mechanisms, Biomarkers, and Therapeutic Opportunities

Percutaneous coronary intervention (PCI) effectively treats flow-limiting coronary lesions but does not eliminate the systemic processes that drive atherosclerotic progression and recurrent events. Residual inflammatory risk (RIR), most commonly identified by persistent elevation of high-sensitivity C-reactive protein (hsCRP), has emerged as an important component of this remaining risk and frequently persists despite intensive lipid lowering. Its interpretation after PCI, however, requires attention to timing, since inflammation related to acute myocardial injury and procedural vascular damage must be distinguished from persistent inflammatory activity after clinical stabilisation. In this review, we examine the biological basis of RIR and its relationship with plaque vulnerability, vascular healing, and recurrent events after coronary intervention. We discuss the role of hsCRP and other circulating biomarkers in post-PCI phenotyping, together with cardiometabolic conditions—including obesity, diabetes, chronic kidney disease, atherogenic dyslipidaemia, and hyperuricaemia—that may sustain inflammatory activation despite successful revascularisation. We also critically appraise the therapeutic evidence. Although CANTOS established inflammation as a modifiable component of atherothrombotic risk and colchicine has shown benefit in selected coronary populations, neutral findings with hyperacute colchicine initiation and, more recently, IL-6 inhibition emphasise that biomarker reduction does not necessarily translate into fewer cardiovascular events. Current guidelines recognise anti-inflammatory therapy in selected settings but do not recommend hsCRP-guided treatment after PCI. RIR therefore represents a clinically relevant post-PCI risk phenotype, but its transition from prognostic marker to actionable treatment target will require better definition of timing, inflammatory pathways, and the patients most likely to benefit from intervention.

Authors

Institutions

Publication Details

Journal
Medical Sciences
Published
2026-10-27
DOI
https://doi.org/10.3390/medsci14070714
Primary Topic
Coronary Interventions and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Residual Inflammatory Risk in Contemporary Coronary Intervention: Mechanisms, Biomarkers, and Therapeutic Opportunities

Polykarpos Patsalis, Athanasios Sakalidis, Mohamad Amer Nashtar, Anastasiοs Apostolos et al.
3 links
Medical Sciences
Coronary Interventions and Diagnostics
article

Residual Inflammatory Risk in Contemporary Coronary Intervention: Mechanisms, Biomarkers, and Therapeutic Opportunities

Polykarpos Patsalis, Athanasios Sakalidis, Mohamad Amer Nashtar, Anastasiοs Apostolos, Vasileios F. Panoulas, Panagiotis Tsioufis, Nikolaos Ktenopoulos, Panagiotis Theofilis, Paschalis Karakasis, K. P. Dimitriadis, Konstantinos P Tsioufis, Obayda Azizy, Panagιotis Iliakis
article en

Abstract

Percutaneous coronary intervention (PCI) effectively treats flow-limiting coronary lesions but does not eliminate the systemic processes that drive atherosclerotic progression and recurrent events. Residual inflammatory risk (RIR), most commonly identified by persistent elevation of high-sensitivity C-reactive protein (hsCRP), has emerged as an important component of this remaining risk and frequently persists despite intensive lipid lowering. Its interpretation after PCI, however, requires attention to timing, since inflammation related to acute myocardial injury and procedural vascular damage must be distinguished from persistent inflammatory activity after clinical stabilisation. In this review, we examine the biological basis of RIR and its relationship with plaque vulnerability, vascular healing, and recurrent events after coronary intervention. We discuss the role of hsCRP and other circulating biomarkers in post-PCI phenotyping, together with cardiometabolic conditions—including obesity, diabetes, chronic kidney disease, atherogenic dyslipidaemia, and hyperuricaemia—that may sustain inflammatory activation despite successful revascularisation. We also critically appraise the therapeutic evidence. Although CANTOS established inflammation as a modifiable component of atherothrombotic risk and colchicine has shown benefit in selected coronary populations, neutral findings with hyperacute colchicine initiation and, more recently, IL-6 inhibition emphasise that biomarker reduction does not necessarily translate into fewer cardiovascular events. Current guidelines recognise anti-inflammatory therapy in selected settings but do not recommend hsCRP-guided treatment after PCI. RIR therefore represents a clinically relevant post-PCI risk phenotype, but its transition from prognostic marker to actionable treatment target will require better definition of timing, inflammatory pathways, and the patients most likely to benefit from intervention.

Medical SciencesVol. 14(7)
Guy's and St Thomas' NHS Foundation Trust (GB), National and Kapodistrian University of Athens (GR), University Hospitals of the Ruhr-University of Bochum (DE), Harefield Hospital (GB), Royal Brompton Hospital (GB), Universitätsklinikum Knappschaftskrankenhaus Bochum (DE), Ippokrateio General Hospital of Thessaloniki (GR), LWL-Universitätsklinikum Bochum (DE), Hippocration General Hospital (GR), Imperial College London (GB), Ruhr University Bochum (DE)
Good health and well-being
Openalex Percentile: Top 10%
Coronary Interventions and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon